China has banned the import of Illumina’s next-generation sequencing (NGS) sequencers as part of retaliatory measures against ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Beijing banned imports of Illumina’s gene-sequencing machines in response to U.S. tariffs.

which analysts believe could significantly expand Illumina's Total (EPA:TTEF) Addressable Market (TAM) by making it easier for new Next-Generation Sequencing (NGS) customers to enter the market.

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...

Illumina Protein Prep™, powered by SOMAmer® technology, a next-generation sequencing (NGS) based solution that will help scale access to proteomic insight Illumina, Inc. (NASDAQ:ILMN ...

The MiSeq desktop sequencer offers low throughput flowcells and long read lengths. It is best for small whole-genome sequencing, targeted gene sequencing, metagenomics, and CRISPR validation. The ...

Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...

Illumina is not banned from operating in the country and will continue to serve its existing customers, a company ...

Medical Device Network · JHVEPhoto via Shutterstock. China has banned the import of Illumina’s next-generation sequencing (NGS) sequencers as part of retaliatory measures against fresh tariffs ...

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...